ProCE Banner Activity

Phase II ABACUS: Neoadjuvant Atezolizumab in Muscle-Invasive Bladder Cancer (Interim Analysis)

Slideset Download
Conference Coverage
Neoadjuvant therapy with atezolizumab yielded a pCR of 29% in cisplatin-ineligible patients with operable bladder cancer.

Released: June 07, 2018

Expiration: June 06, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen